Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease
Objective: Understanding the role of NNMT in initiation and progression of Parkinson's disease (PD). Background: 10-15% of all PD cases are caused by genetic factors,…Creatine for patients with Parkinson’s disease: A meta-analysis
Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…Dynamics in statin use, low density lipoprotein cholesterol levels and Parkinson’s disease. A population-based cohort study using big-data
Objective: To evaluate the association between time-varying statin use and PD risk in a large-scale population-based study. Background: Statins have been shown to downregulate neuroinflammation,…STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort
Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay
Objective: To know the consumption habits of Yerba Mate in a population of Parkinson's disease (PD) patients from Uruguay. To compare the consumption habits of…Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III
Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Risk factors for premature withdraw from the LS-1 PD study
Objective: To identify risk factors for premature withdrawal from a large, multi-center Parkinson's disease clinical trial of possible neuroprotection. Background: Premature withdrawal (PW) of subjects…Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease
Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype
Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.